TFTobias Feuchtinger

Tobias Feuchtinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tobias Feuchtinger has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of a Novel Immunodominant HLA-B*07

    by Patrick S. Günther, Janet K. Peper, Benjamin Faist, Simone Kayser, Lena Hartl, Tobias Feuchtinger, Gerhard Jahn, Michael Neuenhahn, Dirk H. Busch, Stefan Stevanović, et al.

    Adenovirus infections of immunocompromised patients, particularly following allogeneic hematopoietic stem cell transplantation, are associated with morbidity and mortality. Immunotherapy by adoptive transfer of hexon-specific and penton-specific T cells has been successfully applied, but many approaches are impeded by the low number of HLA class I-restricted adenoviral peptide epitopes described to date. We use a novel method to identify naturally presented adenoviral peptide epitopes from infected human cells, ectopically expressing defined HLA, using peptide elution and liquid chromatography-mass spectrometry analysis. We show that the previously described HLA-A*01:01-restricted peptide epitope LTDLGQNLLY from hexon protein is naturally presented, and demonstrate the functionality of LTDLGQNLLY-specific T cells. We further identify a novel immunodominant HLA-B*07:02-restricted peptide epitope VPATGRTLVL from protein 13.6 K, and demonstrate the high proliferative, cytotoxic, and IFN-γ-producing capacity of peptide-specific T cells. Lastly, LTDLGQNLLY-specific T cells can be detected ex vivo following adoptive transfer therapy, and LTDLGQNLLY-specific and VPATGRTLVL-specific T cells have memory phenotypes ex vivo. Given their proliferative and cytotoxic capacity, such epitope-specific T cells are promising candidates for adoptive T-cell transfer therapy of adenovirus infection.


  • Open Access

    Anti‐leukaemic activity of a novel haploidentical‐transplantation approach employing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia

    by Friedhelm R. Schuster, Roland Meisel, Monika Führer, Susanne Reuther, Julia Hauer, Johanna Tischer, Tobias Feuchtinger, Hans‐Jürgen Laws, Hans‐Jochem Kolb, Arndt Borkhardt

    The treatment outcome of children with refractory acute leukaemia or relapse post‐stem cell transplantation is dismal. We report 10 children (non‐remission n = 7) who underwent a new haploidentical transplant approach utilizing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells. Nine patients had successful engraftment and no evidence of leukaemia. Acute and chronic graft‐versus‐host‐disease was observed in five and three patients, respectively; two patients died of treatment‐related toxicity. Seven patients relapsed after 7 (range 3–34) months, however two patients are alive at 6·5 and 7·0 years. This approach provides anti‐leukaemic activity even in heavily pre‐treated children but long‐term disease control requires further intervention.


  • Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation

    by Lena Oevermann, Peter Lang, Tobias Feuchtinger, Michael Schumm, Heiko‐Manuel Teltschik, Patrick Schlegel, Rupert Handgretinger

    Haploidentical hematopoietic stem cell transplantation is a curative alternative option for patients without an otherwise suitable stem cell donor. In order to prevent graft‐versus‐host disease (GvHD), different in vitro and in vivo T cell–depletion strategies have been developed. A delayed immune reconstitution is common to all these strategies, and an impaired immune function after haploidentical transplantation with subsequent infections is a major cause of deaths in these patients. In addition to in vitro and in vivo T cell–depletion methods, posttransplant strategies to rapidly rebuild the immune system have been introduced in order to improve the outcome. Advances in in vitro and in vivo T cell–depletion methods, and adoptive transfer of immune cells of the innate and specific immune system, will contribute to reduce the risk of GvHD, lethal infections, and the risk of relapse of the underlying malignant disease.


  • Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children

    by Patrick Schlegel, Heiko-Manuel Teltschik, Matthias Pfeiffer, Rupert Handgretinger, Michael Schumm, Ewa Koscielniak, Tobias Feuchtinger, Thomas Klingebiel, Peter Bader, Paul-Gerhard Schlegel, et al.


  • Long-Term Remission After First-Line Single-Agent Treatment with Arsenic Trioxide of Relapsed Acute Promyelocytic Leukemia in an 8-Year-Old Boy

    by Martin Ebinger, Carl Philipp Schwarze, Tobias Feuchtinger, Hans-Gerhard Scheel-Walter, Peter Lang, Sibylle Hildenbrand, Peter Gessler, Rupert Handgretinger, Md

    Arsenic trioxide (ATO) has been proven to be highly effective in adults with newly diagnosed or relapsed acute promyelocytic leukemia (APL). Only very limited data are published on the use of ATO as a single agent for first-line therapy of relapsed APL. The authors present a case of a 8-year-old boy with a bone marrow relapse of APL 7 years after first diagnosis, who achieved durable molecular remission with ATO as single agent: induction therapy for 12 weeks, consolidation for 4 weeks, then 6 cycles of 10 days over a period of 6 months. In total, 140 doses of ATO (0.15 mg/kg/day) were given (21 mg/kg). Consecutive promyelocytic leukemia-retinoic acid receptor α (PML-RARα) RT-PCR analyses were negative with a follow-up of 48 months. Acute or late side effects of arsenic were not observed. At present, the boy is in complete remission 4 years after the diagnosis of the relapse.